Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics, Inc. (KROS) has filed a shelf registration to offer, from time to time, up to $350.0 million of common stock, preferred stock, debt securities and/or warrants, including a sales agreement prospectus for up to $100.0 million of common stock under an at-the-market program with Leerink Partners LLC. The $100.0 million ATM capacity is part of, not in addition to, the $350.0 million shelf. Keros is a clinical-stage biopharmaceutical company focused on protein therapeutics targeting dysfunctional transforming growth factor-beta signaling, with lead product candidates rinvatercept and elritercept, the latter licensed ex‑China to Takeda. As a smaller reporting company, it plans to use any net proceeds for general corporate purposes such as R&D, clinical trials, working capital, potential in-licensing or acquisitions, capital expenditures, and possible debt repayment or security repurchases.
Keros Therapeutics, Inc. (KROS) announced that its board of directors approved a new stock repurchase program for up to $5 million of its common stock, to be implemented after receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under a license agreement for elritercept.
As of June 30, 2026, Keros reported $257.6 million in cash and cash equivalents. Based on current operating plans, and after giving effect to the $20 million milestone and the $5 million stock repurchase, Keros anticipates this cash balance will fund operating and capital expenditure requirements into the second half of 2028.
Keros Therapeutics, Inc. (KROS) reported that Annita Tanini, Corp. Controller & VP, Finance, sold 1,224 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share. The company states these were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units, and Ms. Tanini now holds 45,144 shares directly.
Keros Therapeutics, Inc. (KROS) reported that Chief Scientific Officer Lorena Raquel Lerner sold 3,568 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share, in automatic "sell-to-cover" transactions for tax withholding on vesting RSUs. Following these sales, she held 27,559 shares of common stock directly.
Keros Therapeutics, Inc. (KROS) reported a Form 4 for Chief Legal Officer Esther Cho. On 2026-08-18, she sold 4,485 shares of common stock at a weighted average price of $10.29 per share in automatic "sell-to-cover" transactions to satisfy tax withholding on vesting restricted stock units. The sales occurred at prices ranging from $10.14 to $10.50 and were not at her discretion. After these sales, she directly holds 35,770 shares, including 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Keros Therapeutics, Inc. (KROS) director Charles W. Newton reported selling 551 shares of common stock on August 18, 2026 in a transaction coded as an open market or private sale. The weighted average sale price was $10.30 per share, with individual trades between $10.16 and $10.49. After this sale, he directly holds 12,114 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
Keros Therapeutics, Inc. (KROS) director Jean Jacques Bienaime reported an open-market purchase of common stock. On 2026-08-17, he purchased 1,000 shares at a weighted average price of $10.27 per share, executed in multiple trades between $10.02 and $10.39. Following this transaction, he directly holds 19,592 shares of Keros Therapeutics common stock. The purchase was made pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.
Keros Therapeutics, Inc. (KROS) director Charles W. Newton has filed a notice under Rule 144 for a planned sale of common stock through UBS Financial Services Inc. The filing lists a proposed sale of 551 shares of Keros common stock, related to restricted stock units (RSUs) from the issuer with an indicated date of August 15, 2026. The filing also notes a prior sale in the last three months of 550 shares of Keros common stock on June 11, 2026.
Annita Tanini, Corporate Controller and VP, Finance of Keros Therapeutics, Inc., reports her initial beneficial ownership of the company’s equity. She directly holds 46,368 shares of Common Stock, including 11,940 restricted stock units (RSUs) that vest in multiple tranches through 2027, subject to continued service.
She also holds several employee stock options on Common Stock, including options for 25,000 shares at $28.74 per share, 6,000 shares at $70.93, 7,500 shares at $46.30, 10,000 shares at $54.38, 14,800 shares at $56.18, and 7,800 shares at $15.52, with expirations ranging from 2030 to 2036. Certain options are immediately exercisable, while others vest over time in quarterly installments.
Keros Therapeutics provided an updated corporate presentation describing its strategy as a clinical-stage biopharmaceutical company focused on disorders linked to dysfunctional TGF-β superfamily signaling. Lead candidate rinvatercept (KER-065), a modified activin receptor type II ligand trap, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
The presentation reports generally favorable safety and pharmacodynamic data from a Phase 1 healthy volunteer trial and outlines an ongoing open-label Phase 2 basket trial in DMD (about 24 patients) with initial data expected in the first half of 2027. Preclinical data in DMD and ALS models suggest effects on muscle mass, bone, fat, inflammation and neuromuscular junction integrity. A second asset, elritercept (KER-050), is licensed globally (excluding certain Greater China territories) to Takeda, with a $200 million upfront payment, potential milestones of over $1.1 billion, and tiered royalties, alongside the ongoing Phase 3 RENEW trial in myelodysplastic syndromes.